Edap Tms S.a. (NASDAQ:EDAP)

EDAP TMS S.A. (EDAP), incorporated on December 3, 1979, develops and markets the Ablatherm device, an advanced choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option. It is also used for patients who failed a radiotherapy treatment. In addition, the Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company operates in two divisions: high intensity focused ultrasound (HIFU) and urology devices and services (UDS). The HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. EDAP TMS S.A. is a holding company.